Txr1: an important factor in oxaliplatin resistance in gastric cancer

Bi, Jingtao; Bai, Zhigang; Ma, Xuemei; Song, Jianning; Guo, Yantong; Zhao, Jingming; Yi, Xin; Han, Shiwei; Zhang, Zhongtao
February 2014
Medical Oncology;Feb2014, Vol. 31 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin. LIANCHENG LIU; ZHIGANG BAI; XUEMEI MA; TINGTING WANG; YAO YANG; ZHONGTAO ZHANG // Experimental & Therapeutic Medicine;Mar2016, Vol. 11 Issue 3, p846 

    The present study aimed to evaluate the role of taxol resistance gene 1 (Txr1) in the development of oxaliplatin (L-OHP) resistance in gastric cancer (GC). Using SGC-7901 cells as a model, Txr1 was exogenously expressed or knocked down using small interfering RNA. Quantitative polymerase chain...

  • Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells. Mori, Ryutaro; Yoshida, Kazuhiro; Tanahashi, Toshiyuki; Yawata, Kazunori; Kato, Junko; Okumura, Naoki; Tsutani, Yasuhiro; Okada, Morihito; Oue, Naohide; Yasui, Wataru // Gastric Cancer;Jul2013, Vol. 16 Issue 3, p345 

    Background: Oxaliplatin is effective against many types of cancer, and the combination of 5-fluorouracil (5FU) and oxaliplatin is synergistically effective against gastric cancer, as well as colon cancer. The FANCJ protein is one of the Fanconi anemia (FA) gene products, and its interaction with...

  • Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. Qun Zhao; Hui Zhang; Yong Li; Jun Liu; Xiaojie Hu; Liqiao Fan // Journal of Experimental & Clinical Cancer Research (17569966);2010, Vol. 29, p118 

    Background: Drug resistance remains a great challenge in the treatment of gastric cancer. The goal of this study was to explore the anti-tumor effects and mechanism of cytokine-induced killer (CIK) cell combined with oxaliplatin (L-OHP) in human oxaliplatin-resistant gastric cancer cells....

  • Maintenance of Stemness in Oxaliplatin-Resistant Hepatocellular Carcinoma Is Associated with Increased Autocrine of IGF1. Bu, Yang; Jia, Qing-An; Ren, Zheng-Gang; Zhang, Ju-Bo; Jiang, Xue-Mei; Liang, Lei; Xue, Tong-Chun; Zhang, Quan-Bao; Wang, Yan-Hong; Zhang, Lan; Xie, Xiao-Ying; Tang, Zhao-You // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Evidence suggests that many types of cancers are composed of different cell types, including cancer stem cells (CSCs). We have previously shown that the chemotherapeutic agent oxaliplatin induced epithelial-mesenchymal transition, which is thought to be an important mechanism for...

  • Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Koizumi, W.; Takiuchi, H.; Yamada, Y.; Boku, N.; Fuse, N.; Muro, K.; Komatsu, Y.; Tsuburaya, A. // Annals of Oncology;May2010, Vol. 21 Issue 5, p1001 

    Background: The efficacy and safety of oxaliplatin combined with S-1 (SOX regimen) for unresectable advanced or recurrent gastric cancer were investigated.

  • Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Celio, L.; Sternberg, C. N.; Labianca, R.; Torre, I. La; Amoroso, V.; Barone, C.; Pinotti, G.; Cascinu, S.; Costanzo, F. Di; Cetto, G. L.; Bajetta, E. // Annals of Oncology;Jun2009, Vol. 20 Issue 6, p1062 

    Background: This clinical trial assessed the efficacy of pemetrexed combined with oxaliplatin (PEMOX) in patients with advanced gastric cancer (AGC).

  • Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing. Podolski-Renić, Ana; Jadranin, Milka; Stanković, Tijana; Banković, Jasna; Stojković, Sonja; Chiourea, Maria; Aljančić, Ivana; Vajs, Vlatka; Tešević, Vele; Ruždijić, Sabera; Gagos, Sarantis; Tanić, Nikola; Pešić, Milica // Cancer Chemotherapy & Pharmacology;Sep2013, Vol. 72 Issue 3, p683 

    Purpose: Multi-drug resistance (MDR) is a major obstacle to successful cancer treatment. Therefore, in vitro models are necessary for the investigation of the phenotypic changes provoked by cytotoxic agents and more importantly for preclinical testing of new anticancer drugs. Methods: We...

  • Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. Wang, Sisi; Zhang, Hongyong; Scharadin, Tiffany M.; Zimmermann, Maike; Hu, Bin; Pan, Amy Wang; Vinall, Ruth; Lin, Tzu-yin; Cimino, George; Chain, Patrick; Vuyisich, Momchilo; Gleasner, Cheryl; Mcmurry, Kim; Malfatti, Michael; Turteltaub, Kenneth; de Vere White, Ralph; Pan, Chong-xian; Henderson, Paul T. // PLoS ONE;1/22/2016, Vol. 11 Issue 1, p1 

    We report herein the development, functional and molecular characterization of an isogenic, paired bladder cancer cell culture model system for studying platinum drug resistance. The 5637 human bladder cancer cell line was cultured over ten months with stepwise increases in oxaliplatin...

  • p53-Mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Toscano, F.; Fajoui, Z. El; Gay, F.; Lalaoui, N.; Parmentier, B.; Chayvialle, J.-A.; Scoazec, J.-Y.; Micheau, O.; Abello, J.; Saurin, J.-C. // Oncogene;7/10/2008, Vol. 27 Issue 30, p4161 

    Oxaliplatin has emerged as a major chemotherapeutic drug in the treatment of advanced colorectal cancer, yet like most conventional cancer therapeutics, its efficacy is often compromised due to p53 mutations. Unlike oxaliplatin, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)...

  • Oxaliplatin.  // Reactions Weekly;8/14/2010, Issue 1314, p33 

    The article describes the case of a 76-year-old woman with gastric cancer who developed immune-mediated pancytopenia during oxaliplatin therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics